Advertisement

Elanco Animal Health Incorporated ELAN

Set alert

Price alert · ELAN

All alert types
23.06 USD -0.18 -0.77%

At close · Oct 30

23.05 -0.01 -0.03%

After hours · Oct 30, 5:05 PM ET

Bid
23.05 × 500
Ask
23.06 × 700
22.93 Day range 23.48
19.80 52-week range 26.84
YTD
+1.90%
1 year
+2.17%
Open
23.48
Prev close
23.24
Mkt cap
11.52B
Vol
3.45M
Avg vol
6.15M
EPS
-0.41
P/E
0.00
Div yield
0.00%
More statistics
Low
22.93
High
23.48
Forward P/E
18.12
Beta
1.71
Short ratio
5.57
Inst. own
115.51%
Dividend
0.00
Ex-div date
Earnings
Nov 6, 2026
50-d avg
23.13
200-d avg
23.80
1y target
30.23

2Y chart

Chart tools
Interval

Events in this range
  • Aug 7, 2025Earnings: 0.26; estimate 0.2; surprise 30%
  • Nov 5, 2025Earnings: 0.19; estimate 0.13; surprise 46.15%
  • Feb 24, 2026Earnings: 0.13; estimate 0.11; surprise 18.18%
  • May 6, 2026Earnings: 0.4; estimate 0.3456; surprise 15.74%
  • Jul 22, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
  • Aug 5, 2026Earnings: 0.34; estimate 0.2692; surprise 26.3%
  • Aug 6, 2026Rating: Keybanc · Overweight → Overweight
  • Aug 6, 2026Rating: UBS · Buy → Buy
  • Oct 16, 2026Rating: Goldman Sachs · — → Buy
  • Oct 20, 2026Downgrade: Jefferies · Buy → Hold
  • Oct 29, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
Signals (95)
NameDateAgo
SMA: BearishOct 30, 20262 days ago
SMA: BullishOct 29, 20263 days ago
SMA: BearishOct 20, 20261 week ago
SMA: BullishOct 15, 20262 weeks ago
MACD: Buy SignalOct 5, 20263 weeks ago
SMA: BearishSep 9, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BearishSep 3, 20261 month ago
SMA: BullishSep 2, 20262 months ago
SMA: BearishAug 27, 20262 months ago
SMA: BullishAug 25, 20262 months ago
SMA: BullishAug 21, 20262 months ago
MACD: Buy SignalAug 21, 20262 months ago
SMA: BearishAug 20, 20262 months ago
SMA: BullishAug 14, 20262 months ago
SMA: BearishAug 7, 20262 months ago
SMA: BearishAug 6, 20262 months ago
MACD: Sell SignalAug 4, 20262 months ago
MACD: Buy SignalJul 29, 20263 months ago
MACD: Sell SignalJul 22, 20263 months ago
MACD: Buy SignalJul 13, 20263 months ago
MACD: Sell SignalJul 10, 20263 months ago
MACD: Buy SignalJun 26, 20264 months ago
MACD: Sell SignalJun 22, 20264 months ago
SMA: BullishJun 11, 20264 months ago
SMA: BearishJun 10, 20264 months ago
SMA: BullishMay 27, 20265 months ago
SMA: BullishMay 26, 20265 months ago
MACD: Buy SignalMay 26, 20265 months ago
MACD: Sell SignalMay 12, 20265 months ago
SMA: BearishMay 11, 20265 months ago
SMA: BullishMay 6, 20265 months ago
MACD: Buy SignalMay 5, 20266 months ago
MACD: Sell SignalApr 21, 20266 months ago
MACD: Buy SignalApr 14, 20266 months ago
MACD: Sell SignalMar 27, 20267 months ago
SMA: BearishMar 26, 20267 months ago
SMA: BullishMar 24, 20267 months ago
SMA: BearishMar 20, 20267 months ago
MACD: Buy SignalMar 19, 20267 months ago
SMA: BullishMar 17, 20267 months ago
SMA: BearishMar 5, 20268 months ago
MACD: Sell SignalMar 3, 20268 months ago
MACD: Buy SignalFeb 24, 20268 months ago
MACD: Sell SignalFeb 13, 20268 months ago
MACD: Buy SignalFeb 10, 20268 months ago
MACD: Sell SignalJan 28, 20269 months ago
MACD: Buy SignalDec 19, 202510 months ago
SMA: BullishDec 15, 202510 months ago
SMA: BearishDec 9, 202510 months ago
MACD: Sell SignalDec 3, 202511 months ago
MACD: Buy SignalNov 25, 202511 months ago
MACD: Sell SignalNov 5, 202512 months ago
RSI: OverboughtNov 3, 202512 months ago
MACD: Buy SignalOct 20, 20251 year ago
RSI: OverboughtOct 17, 20251 year ago
MACD: Sell SignalOct 9, 20251 year ago
RSI: OverboughtOct 6, 20251 year ago
RSI: OverboughtOct 1, 20251 year ago
MACD: Buy SignalSep 30, 20251 year ago
RSI: OverboughtSep 8, 20251 year ago
MACD: Sell SignalSep 2, 20251 year ago
RSI: OverboughtAug 22, 20251 year ago
SMA: BullishAug 7, 20251 year ago
MACD: Buy SignalAug 7, 20251 year ago
RSI: OverboughtAug 7, 20251 year ago
SMA: BearishAug 6, 20251 year ago
SMA: BullishAug 5, 20251 year ago
SMA: BearishJul 31, 20251 year ago
MACD: Sell SignalJul 15, 20251 year ago
RSI: OverboughtJul 10, 20251 year ago
MACD: Buy SignalJul 8, 20251 year ago
MACD: Sell SignalJul 7, 20251 year ago
MACD: Buy SignalJul 2, 20251 year ago
RSI: OverboughtJul 2, 20251 year ago
RSI: OverboughtJun 6, 20251 year ago
MACD: Sell SignalJun 3, 20251 year ago
RSI: OverboughtMay 28, 20251 year ago
RSI: OverboughtMay 12, 20251 year ago
SMA: BullishMay 7, 20251 year ago
RSI: OverboughtMay 7, 20251 year ago
MACD: Buy SignalApr 23, 20251 year ago
RSI: OversoldApr 7, 20251 year ago
MACD: Sell SignalApr 3, 20251 year ago
MACD: Buy SignalMar 18, 20251 year ago
MACD: Sell SignalMar 11, 20251 year ago
MACD: Buy SignalMar 7, 20251 year ago
MACD: Sell SignalMar 4, 20251 year ago
MACD: Buy SignalMar 3, 20251 year ago
MACD: Sell SignalFeb 7, 20251 year ago
MACD: Buy SignalFeb 5, 20251 year ago
MACD: Sell SignalFeb 4, 20251 year ago
SMA: BearishJan 31, 20251 year ago
SMA: BullishJan 30, 20251 year ago
MACD: Buy SignalDec 27, 20241 year ago

Key statistics

Market cap
11.52B
Enterprise value
15.31B
Trailing P/E
0.00
Forward P/E
18.12
PEG ratio
4.04
Price / sales
2.30
Price / book
1.75
EPS (TTM)
-0.41
Beta
1.71
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-3.96%
Revenue (TTM)
5.02B
Revenue growth
10.20%
Free cash flow
826.88M
Total cash
530.00M
Total debt
4.23B
Return on equity
-2.98%
Shares outstanding
499.62M
Short % of float
9.89%
50-day average
23.13
200-day average
23.80

Analyst view

Consensus: buy

Buy
Price target (mean) 30.23 +31.1% upside
Target (low)
24.00
Target (mean)
30.23
Target (high)
34.00
Ratings (0m) 16 13 buy · 3 hold · 0 sell
  • Strong buy4
  • Buy9
  • Hold3
  • Sell0
  • Strong sell0

Next earnings

Nov 6, 2026

Expected Nov 6, 2026. Consensus EPS estimate 0.20328.

Earnings history

Financials — quick view

All financials
ELAN Revenue — quarterly 1.37B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ELAN Net income — quarterly 54.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ELAN EPS — quarterly 0.11
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ELAN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2026Sep 30, 20260.2028———
Aug 5, 2026Jun 30, 20260.26920.34+0.07+26.30%
May 6, 2026Mar 31, 20260.34560.40+0.05+15.74%
Feb 24, 2026Dec 31, 20250.110.13+0.02+18.18%
Nov 5, 2025Sep 30, 20250.130.19+0.06+46.15%
Aug 7, 2025Jun 30, 20250.200.26+0.06+30.00%

Upgrades / downgrades

ELAN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 20, 2026JefferiesdownBuyHold
Oct 16, 2026Goldman Sachsinit—Buy
Aug 6, 2026UBSmainBuyBuy
Aug 6, 2026KeybancmainOverweightOverweight
Jul 22, 2026Morgan StanleymainEqual-WeightEqual-Weight

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
elanco.com

News

Your note

Sign in to keep a note on ELAN — it syncs with the Stock Master app.

Insider holders

ELAN insider holders
InsiderRelationLatest transactionDateShares held
BETTINGTON TIMOTHY JOfficerSaleOct 14, 2026138,911
CABRAL RAMIRO MARTINOfficerStock Award(Grant)Feb 26, 2026290,366
DE BRABANDER ELLENOfficerStock Award(Grant)Mar 31, 2026280,821
HOOVER R DAVIDDirectorStock Award(Grant)May 20, 2026277,371
KINARD DAVID SOfficerStock Award(Grant)Feb 26, 2026217,697
KURZIUS LAWRENCE ERIKDirectorPurchaseAug 19, 2026188,647

Institution ownership

ELAN institution ownership
Holder% heldSharesValueReported
Dodge & Cox Inc.13.49%67,397,0251.55BJun 29, 2026
FMR, LLC11.40%56,948,8191.31BJun 29, 2026
Blackrock Inc.9.78%48,849,9731.13BJun 29, 2026
Primecap Management Company9.10%45,445,0121.05BJun 29, 2026
T. Rowe Price Investment Management, Inc.5.75%28,750,719662.99MJun 29, 2026
Dimensional Fund Advisors LP5.09%25,417,271586.12MJun 29, 2026

Fund ownership

ELAN fund ownership
Holder% heldSharesValueReported
Dodge & Cox Funds-Dodge & Cox Stock Fund8.63%43,107,500994.06MJun 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%17,796,673410.39MSep 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund3.55%17,751,139409.34MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%15,872,148366.01MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%11,448,318264.00MJun 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 2.07%10,339,390238.43MAug 30, 2026
Advertisement